Agios (NASDAQ: AGIO) outlines 2026 milestones for J.P. Morgan event

Rhea-AI Filing Summary

Agios Pharmaceuticals furnished an update on its plans for 2026. On January 12, 2026, the company issued a press release outlining its anticipated 2026 milestones, timed around its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The press release is provided as Exhibit 99.1 and the conference presentation slides as Exhibit 99.2. This information is furnished under a Regulation FD disclosure and is not treated as filed for liability purposes or automatically incorporated into other securities law filings.

0001439222FALSE00014392222026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Agios Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-36014

26-0662915

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

88 Sidney Street,

Cambridge,

MA

02139

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 649-8600

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.001 per share

AGIO

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 12, 2026, Agios Pharmaceuticals, Inc. (the “Company”) issued a press release outlining its anticipated 2026 milestones, which will be discussed at the Company’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The slides to be presented by the Company at the 44th Annual J.P. Morgan Healthcare Conference are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.			Description
99.1			Press release issued January 12, 2026
99.2			Presentation at the 44th Annual J.P. Morgan Healthcare Conference
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AGIOS PHARMACEUTICALS, INC.
Date: January 12, 2026			By:			/s/ Brian Goff
						Brian Goff Chief Executive Officer

FAQ

What did Agios (AGIO) disclose in this 8-K filing?

Agios Pharmaceuticals furnished a press release and investor presentation that outline its anticipated 2026 milestones and will be discussed at the 44th Annual J.P. Morgan Healthcare Conference.

Which exhibits are included in Agios (AGIO) January 12, 2026 8-K?

The filing includes Exhibit 99.1, a press release issued January 12, 2026, Exhibit 99.2, a presentation for the 44th Annual J.P. Morgan Healthcare Conference, and Exhibit 104, the cover page Inline XBRL data file.

How will Agios (AGIO) share its 2026 milestones with investors?

Agios plans to discuss its anticipated 2026 milestones in a press release and in slides presented at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

Is the information in Agios (AGIO) Exhibit 99.1 and 99.2 considered filed with the SEC?

No. The company states that the information in Item 7.01, including Exhibits 99.1 and 99.2, is furnished, not filed, and is not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.

What SEC item does this Agios (AGIO) 8-K use for the disclosure?

The disclosure is made under Item 7.01, which relates to Regulation FD disclosure of information to the market.